全文获取类型
收费全文 | 257篇 |
免费 | 12篇 |
专业分类
儿科学 | 47篇 |
基础医学 | 28篇 |
口腔科学 | 1篇 |
临床医学 | 20篇 |
内科学 | 54篇 |
皮肤病学 | 9篇 |
神经病学 | 22篇 |
外科学 | 44篇 |
综合类 | 2篇 |
预防医学 | 1篇 |
眼科学 | 1篇 |
药学 | 24篇 |
中国医学 | 3篇 |
肿瘤学 | 13篇 |
出版年
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 7篇 |
2014年 | 4篇 |
2013年 | 3篇 |
2012年 | 4篇 |
2011年 | 3篇 |
2010年 | 8篇 |
2009年 | 6篇 |
2008年 | 2篇 |
2007年 | 5篇 |
2006年 | 14篇 |
2005年 | 2篇 |
2004年 | 11篇 |
2003年 | 10篇 |
2002年 | 2篇 |
2001年 | 2篇 |
2000年 | 2篇 |
1999年 | 3篇 |
1998年 | 24篇 |
1997年 | 12篇 |
1996年 | 20篇 |
1995年 | 28篇 |
1994年 | 9篇 |
1993年 | 10篇 |
1992年 | 3篇 |
1991年 | 3篇 |
1989年 | 2篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 4篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1977年 | 2篇 |
1974年 | 1篇 |
1969年 | 1篇 |
1967年 | 2篇 |
1964年 | 4篇 |
1963年 | 1篇 |
1959年 | 1篇 |
1958年 | 1篇 |
1957年 | 3篇 |
1956年 | 7篇 |
1955年 | 7篇 |
1954年 | 9篇 |
排序方式: 共有269条查询结果,搜索用时 15 毫秒
31.
N. WADA N. OHARA M. KAMEOKA Y. NISHINO S. MATSUMOTO T. NISHIYAMA M. NAITO H. YUKITAKE Y. OKADA K. IKUTA & T. YAMADA 《Scandinavian journal of immunology》1996,43(2):202-209
The recombinant bacillus Calmette–Guérin (rBCG) secretion system utilizing an extracellular α antigen of Mycobacterium kansasii (α-K) was characterized biochemically and immunologically. The human immunodeficiency virus type1 (HIV-1) p17 gag B cell epitope fused to α-K was secreted in extremely large amounts. At least three mice out of seven inoculated with rBCG generated high titres of antibody to the epitope. The long-lasting antibody production persisted more than 14 months. 相似文献
32.
MAMI MURAI-KUSHIYA SATOSHI OKADA TOSHIO KIMURA RYUICHI HASEGAWA 《The Journal of pharmacy and pharmacology》1993,45(9):836-838
Abstract— Turpentine oil treatment (0·2 mL kg?1, s.c.) was used to increase the plasma concentration of α1-acid glycoprotein (0·13 mg mL?1 in control rats) to 1·72 mg mL?1 after 2 days, and allow assessment of its effects on the pharmacokinetics and stereoselective binding of three β-blockers. Racemates (5 mg kg?1) were administered intravenously to control and turpentine oil-pretreated rats and the plasma concentrations were determined up to 90 min. Stereoselective analysis showed the apparent distribution volume and the area under plasma concentration-time curves (AUC) of R-(+)-propranolol to be, respectively, one-quarter and twice those of the S-(–)-enantiomer and differences in pharmacokinetic parameters between the two were magnified by turpentine oil pretreatment. Pharmacokinetic parameters of oxprenolol enantiomers were essentially similar for the controls but after turpentine oil pretreatment, a higher affinity of the R-(+)-enantiomer for plasma was observed. Acebutolol enantiomers behaved non-stereospecifically throughout. These results were consistent with predictions from the in-vitro stereospecific binding properties of these agents to purified rat α1-acid glycoprotein. 相似文献
33.
KOICHI KUSUHARA KOHJI UEDA KEN TOKUGAWA CHIAKI MIYAZAKI KENJI OKADA TAKASHI SAWADA 《Pediatrics international》1995,37(5):651-653
Antibody to p40tax (anti-p40tax) in serum specimens obtained sequentially from a human T cell lymphotropic virus type I carrier population of mothers and children were assayed. The prevalences of anti-p40tax at the initial sampling were 88% (7/8) in children and 55% (16/29) in mothers. Two of the seven positive children lost their anti-p40tax during the investigation period, resulting in a final prevalence of 63% (5/8) in children. However, anti-p40tax status was constant in all the 22 mothers with multiple serum samples (15 remained positive and seven remained negative). A decline in the absorbance value of EIA for anti-p40tax was observed in seven of the 15 anti-p40tax positive mothers. This decline may result in the disappearance of anti-p40tax in some of them. 相似文献
34.
ATSUYUKI KOHARA MASAMICHI OKADA RIE TSUTSUMI KAZUSHIGE OHNO MASAYASU TAKAHASHI MASAO SHIMIZU-SASAMATA JUN-ICHI SHISHIKURA HIROSHI INAMI SHUICHI SAKAMOTO TOKIO YAMAGUCHI 《The Journal of pharmacy and pharmacology》1998,50(7):795-801
The in-vitro pharmacological properties of (2,3-dioxo-7-(1H-imidazol-***1-yl)-6-nitro-1,2,3,4-tetrahydro-1-quinoxalinyl)-acetic acid monohydrate, YM872, a novel and highly water-soluble α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)-receptor antagonist were investigated. YM872 is highly water soluble (83 mg mL?1 in Britton-Robinson buffer) compared with 2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo(F)quinoxaline (NBQX), 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) or 6-cyano-7-nitroquinoxa-line-2,3-dione (CNQX). YM872 potently inhibits [3H]AMPA binding with a Ki (apparent equilibrium dissociation constant) value of 0.096 ± 0.0024 μM. However, YM872 had very low affinity for other ionotropic glutamate receptors, as measured by competition with [3H]kainate (high-affinity kainate binding site, concentration resulting in half the maximum inhibition (IC50) = 4.6 ± 0.14 μm), [3H]glutamate (N-methyl-D-aspartate (NMDA) receptor glutamate binding site, IC50 > 100 μM) and [3H]glycine (NMDA receptor glycine-binding site, IC50 > 100 μM). YM872 competitively antagonized kainate-induced currents in Xenopus laevis oocytes which express rat AMPA receptors, with a pA2 value of 6.97 ± 0.01. In rat hippocampal primary cultures, YM872 blocked a 20-μM AMPA-induced increase of intracellular Ca2+ concentration with an IC50 value of 0.82 ± 0.031 μM, and blocked 300-μM kainate-induced neurotoxicity with an IC50 value of 1.02 μM. These results show that YM872 is a potent and highly water-soluble AMPA antagonist with great potential for treatment of neurodegenerative disorders such as stroke. 相似文献
35.
36.
MASAKO YAMAGUCHI SEIICHIRO KAMIMURA JUNICHI TAKADA KAORU IWATA TAKESHI IIDA KAZUO KOBAYASHI HAJIME NAKANO YASUHIRO OKADA SATORU FUJIIMI TETSURO SOHDA NAOMI HIZUKA 《Journal of gastroenterology and hepatology》1998,13(1):47-51
This case of hepatocellular carcinoma (HCC) with alcoholic liver fibrosis, which was not associated with hepatitis viruses, was accompanied by hypoglycaemia. The immunoreactive insulin level was low and other hormonal examinations were almost normal. Immunohistochemical studies showed a high level of insulin-like growth factor II (IGF2) peptide in the HCC section and the size heterogeneity of serum IGF2 investigated by western blot revealed a large form at approximately 15 kDa. These results suggest that the HCC with alcoholic liver fibrosis produced IGF2 and that the hypoglycaemia was caused by tumour-associated IGF2. 相似文献
37.
38.
Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder 总被引:10,自引:0,他引:10
ISAO HARA HIDEAKI MIYAKE YOSHIZUMI TAKECHI HIROSHI ETO AKINOBU GOTOH MASATO FUJISAWA HIROSHI OKADA SOICHI ARAKAWA SADAO KAMIDONO KOBE UROGENITAL TUMOR STUDY GROUP 《International journal of urology》2003,10(1):19-24
BACKGROUND: The objective of this study was to retrospectively investigate the effectiveness of transurethral resection of bladder tumor (TURBT) and intravesical instillation therapy for stage T1, grade 3 (T1G3) transitional cell carcinoma (TCC) of the urinary bladder. METHODS: Between January 1995 and December 1997, 97 patients with T1G3 TCC of the urinary bladder were treated by TURBT and adjuvant intravesical instillation with bacillus Calmette-Guérin (BCG) or other anticancer agents. The recurrence-free survival rates were evaluated according to several clinicopathological factors. The cases that progressed to muscle invasive disease were also analysed. RESULTS: In this series, the median follow-up period was 25 months (range, 5- 41) after the initial TURBT. Intravesical recurrence was noted in 44 patients (45%), and the 1, 2, and 3 year recurrence-free survival rates were 72%, 58%, and 42%, respectively. Multivariate analyses revealed that the risk of intravesical recurrence was significantly higher for patients who did not receive BCG therapy, irrespective of age, gender, tumor size, multiplicity, pathological stage, concomitant carcinoma in situ, and lymphovascular involvement. Moreover, after a median of 10 months, disease progression occurred in seven patients (7%), of which only one patient was treated by BCG therapy after initial TURBT. CONCLUSION: These findings suggest that intravesical instillation with BCG combined with TURBT is an effective conservative treatment for T1G3 TCC of the bladder. Patients with negative prognostic factors should be treated by BCG rather than other anticancer agents after TURBT. 相似文献
39.
40.